Clinical trials
Completed Carotid Stenosis trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
157 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 3 |
| 2002 | 2 |
| 2003 | 4 |
| 2004 | 1 |
| 2005 | 4 |
| 2006 | 6 |
| 2007 | 8 |
| 2008 | 5 |
| 2009 | 4 |
| 2010 | 4 |
| 2011 | 9 |
| 2012 | 5 |
| 2013 | 12 |
| 2014 | 7 |
| 2015 | 9 |
| 2016 | 12 |
| 2017 | 10 |
| 2018 | 7 |
| 2019 | 6 |
| 2020 | 5 |
| 2021 | 6 |
| 2022 | 12 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 157 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 4 |
| National Heart, Lung, and Blood Institute (NHLBI) | 4 |
| Silk Road Medical | 4 |
| University Hospital Ostrava | 4 |
| W.L.Gore & Associates | 4 |
| Columbia University | 3 |
| Contego Medical, Inc. | 3 |
| Mayo Clinic | 3 |
| Assistance Publique - Hôpitaux de Paris | 2 |
| Helios Research Center | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carotid Stenosis | 157 |
| Stroke | 38 |
| Atherosclerosis | 24 |
| Carotid Artery Diseases | 22 |
| Ischemic Attack, Transient | 12 |
| Cardiovascular Diseases | 11 |
| Ischemic Stroke | 9 |
| Constriction, Pathologic | 8 |
| Diabetes Mellitus | 8 |
| Aortic Aneurysm, Abdominal | 7 |
Trials
Showing 51 to 75 of 157. Each trial links to its page on Pharma Observatory.
57 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.